N-(4-(3-(diethylamino)propoxy)phenyl)-4-(4-methylpiperidin-1-yl)pyrimidin-2-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-(4-(3-(diethylamino)propoxy)phenyl)-4-(4-methylpiperidin-1-yl)pyrimidin-2-amine
• 英文别名: N-[4-[3-(diethylamino)propoxy]phenyl]-4-(4-methylpiperidin-1-yl)pyrimidin-2-amine
• 化学式: C₂₃H₃₅N₅O
• 分子量: 397.564
• InChiKey: BMAKXVPKOLXLPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  29
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  53.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-二乙氨基-1-丙醇 在 盐酸 、 tin(II) chloride dihdyrate 、 偶氮二甲酸二异丙酯 、 溶剂黄146 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 20.0h， 生成 N-(4-(3-(diethylamino)propoxy)phenyl)-4-(4-methylpiperidin-1-yl)pyrimidin-2-amine
  参考文献：
  名称：

  Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468

  摘要：

  Triple-negative breast cancers (TNBCs) are characterized as an invasive and intractable subtype of breast cancers. Overexpression of epidermal growth factor receptor (EGFR) has been considered to be an important target for TNBC therapy, but efficacies of EGFR inhibitors in clinical trials are elusive. In this study, novel series of 2-anilinopyrimidines were synthesized in an effort to identify selective inhibitors against an EGFR-overexpressing TNBC cell line. Biological evaluation demonstrated that compounds 21 and 38, with a 4-methylpiperidine group and a high ClogP value, exhibited good potency and selectivity for the TNBC cell line. This study has provided evidence to support further development of 2-anilinopyrimidine-based TNBC selective inhibitors and investigation of the targets of compounds 21 and 38.

  DOI：

  10.1016/j.bmcl.2018.11.010

文献信息

• Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468
  作者：Jeyun Jo、Sou Hyun Kim、Heegyu Kim、Myeonggyo Jeong、Jae-Hwan Kwak、Young Taek Han、Jee-Yeong Jeong、Young-Suk Jung、Hwayoung Yun

  DOI：10.1016/j.bmcl.2018.11.010

  日期：2019.1

  Triple-negative breast cancers (TNBCs) are characterized as an invasive and intractable subtype of breast cancers. Overexpression of epidermal growth factor receptor (EGFR) has been considered to be an important target for TNBC therapy, but efficacies of EGFR inhibitors in clinical trials are elusive. In this study, novel series of 2-anilinopyrimidines were synthesized in an effort to identify selective inhibitors against an EGFR-overexpressing TNBC cell line. Biological evaluation demonstrated that compounds 21 and 38, with a 4-methylpiperidine group and a high ClogP value, exhibited good potency and selectivity for the TNBC cell line. This study has provided evidence to support further development of 2-anilinopyrimidine-based TNBC selective inhibitors and investigation of the targets of compounds 21 and 38.